Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The ...
Investor's Business Daily on MSN11h
Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And AlphabetThe week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...
Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Hosted on MSN18h
4 Healthcare Stocks Poised to Crush Q4 Earnings EstimatesThe fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports ...
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...
Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback